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The Focal adhesion kinase (FAK) is a ubiquitous cytoplasmic tyrosine-kinase promoting tumor progression and metastasis
processes by acting in cancer cells and their tumor microenvironment partners. FAK overexpression in primary colon tumors
and their metastasis is associated to poor colorectal cancer (CRC) patients’ outcome. Eight FAK mRNA alternative splice
variants have been described and contribute to additional level of FAK activity regulation, some of them corresponding to
overactivated FAK isoforms. To date, FAK mRNA alternative splice variants expression and implication in CRC processes remain
unknown. Here, using different human CRC cells lines displaying differential invasive capacities in an in vivo murine model
recapitulating the different steps of CRC development from primary tumors to liver and lung metastasis, we identiﬁed three out
of the eight mRNA variants (namely FAK0, FAK28 and FAK6) differentially expressed along the CRC process and the tumor sites.
Our results highlight an association between FAK0 and FAK6 expressions and the metastatic potential of the most aggressive
cell lines HT29 and HCT116, suggesting that FAK0 and FAK6 could represent aggressiveness markers in CRC. Our ﬁndings also
suggest a more speciﬁc role for FAK28 in the interactions between the tumors cells and their microenvironment. In conclusion,
targeting FAK0, the common form of FAK, might not be a good strategy based on the numerous roles of this kinase in
physiological processes. In contrast, FAK6 or FAK28 splice variants, or their corresponding protein isoforms, may putatively
represent future therapeutic target candidates in the development of CRC primary tumors and metastasis.
Introduction
Along development, cells have elaborated Alternative Splicing
(AS) of messenger ribonucleic acid (mRNA) in order to
increase the ﬁne-tuning of protein functions. AS is a substitute
to the regular constitutive splicing where intron removal and
exon ligation are performed in the order of introns and exons
within the gene sequence. In AS, due to weak splicing signals,
shorter exon or high sequence conservation either sides of
orthologous alternative exons, certain exons are bypassed by
the spliceosome leading to various forms of mature mRNA.1
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Thus, by generating from an initial unique premessenger RNA,
different protein isoforms varying in terms of expression, subcellu-
lar localization, interactions and activities, AS represents a critical
player in protein function regulation in development, physiology
and disease.2 Indeed, AS directly inﬂuences carcinogenesis and
metastasis, and some alternative mRNAs splice variants are pro-
posed as early markers in diagnosis and as therapeutic targets.3
For instance, splice variants of the Focal Adhesion Kinase (FAK)
are abnormally expressed in the primitive leukemic cells of
patients suffering of acute myeloid leukemia (AML) presenting a
poor prognostic,4 and may represent potential biomarkers for
FAK-targeted therapies in non small cell lung cancers.5
FAK is a cytoplasmic tyrosine kinase activated by growth
factors and integrins. Alternative splicing of FAK pre-mRNA
allows the inclusion, independently of each other, of the exons
13, 14, 16, and 31, respectively coding for the boxes 28, 6, 7, and
Pro-Trp-Arg (PWR, characterizing FAK+ which has only been
described in neurons)6 (Fig. 1). The most common form FAK0,
ubiquitously expressed, contains none of these four exons. The
FAK28 splice variant, including exon 13 coding for a peptide
fragment of 28 amino acids (box 28), juxtaposed in N-terminal
to the box 67 displays a pattern of progressive increased expres-
sion toward adulthood, but the box 28 function in the regulation
of FAK remains unknown.6 FAK6 and FAK7 splice variants,
respectively including exons 14 or 16, have a peak of expression
at the ﬁnal stages of the embryonic development. From a func-
tional point of view, the inclusion of boxes 6 and/or 7 results in
constitutively active FAK protein isoforms8 that could strongly
enhance the activity of Src kinases, a proximal signaling partner
of FAK, which plays a key role in the metastasis process.9 Thus,
depending on the association of speciﬁc exons (e.g. FAK6,7,28),
the expression of some splice variants can be either ubiquitous
or tissue speciﬁc, stage speciﬁc or detected throughout the life-
time. So far, FAK splice variants have been mainly studied in the
brain. However FAK6,7, FAK28,6,7 and FAK28 have been found in
the liver, a tissue of endodermal origin like the intestine. Impor-
tantly and as previously mentioned, our previous work in leuke-
mia4 and the recent data obtained by Zhou and collaborators
in non small cell lung cancer,5 both demonstrated that FAK6
expression is related to the tumor state and correlated to an
aggressive tumor phenotype in patients.
In addition to its enzymatic activity, FAK is also a scaffold
protein allowing the interaction between integrins, compo-
nents of the focal contacts and the actin network, and thus
functions as a biosensor to control cell adhesion and the inter-
action of the cell with its environment. Consequently, FAK is
a major player in cell migration and invasion. Colorectal can-
cer (CRC) is the third cause of cancer-related death, mainly
due its high metastatic potential. In the colon, this kinase
plays critical roles in regeneration and tumorigenesis.10 After
the tissue damage in the colon, FAK is overexpressed and is
required for stem cell and progenitor proliferation and migra-
tion.10 Ashton et al. also reported that the dysregulation of
the Wnt/β-catenin pathway activates c-myc that, in turn, pro-
motes FAK gene transcription. Importantly, FAK regulates
pathways such as APC/β-catenin, Raf/Ras, PI3K/mTOR and
BMP/Smad, which are all dysregulated in CRC. Moreover,
FAK overexpression is an independent bad prognostic factor
in colorectal cancer.11 Clinical data report that FAK mRNA
and protein expression levels are increased in CRC primary
tumors and their matched metastases in the liver when compared
to normal colorectal mucosa.12 Importantly, in unmatched speci-
mens, FAK protein is overexpressed in metastases compared to
primary tumors, whereas in matched samples its expression was
equivalent.12 This suggests that primary tumors with higher FAK
expression are more efﬁcient to produce liver metastases in line
with the known role of FAK in the promotion of cell migration
and invasion.13
Figure 1. Domain composition of FAK. The protein sequence is indicated without the alternatively spliced exons, which are represented as
boxes above the sequence, with the corresponding number of amino acids that they insert (28, 6, 7 or 3). The N-terminal band FERM domain
is indicated in yellow, the catalytic tyrosine kinase domain is shown in red, the Proline-Rich regions are shown in blue and the FAT domain in
green. The positions of the autophosphorylated tyrosine residues (397) and those of other tyrosines phosphorylated by p60-Src kinases are
indicated in orange under the protein sequence.
What’s new?
Overexpression of the focal adhesion kinase (FAK) is associated with poor outcome in patients with colorectal cancer but the
role of the eight splice variants of FAK remains unknown. Here the authors correlated FAK splice variant expression in
colorectal tumor cell lines with invasiveness in mouse models. FAK0 and FAK6 splice variant expression was associated with
higher aggressiveness and metastatic potential, underscoring that distinct FAK splice variants may represent new targets in
the development of drugs against colorectal cancer and associated metastasis.
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In order to decipher the putative different involvement of
FAK splice variants along CRC processes, we investigated the
pattern of expression of FAK spliced mRNA variants at both
the primary tumor site and in liver metastasis, using a patho-
physiological murine model of primary and metastatic CRC.14
Material and Methods
Human cell lines and tissues
The human colon carcinoma cell lines HT29, HCT116,
SW480 and SW620, were purchased from the American Type
Culture Collection (ATCC). While HT29, HCT116 and
SW480 cell lines were established from primary tumors,
SW620 cell line was established from a lymph node metastasis
from a colorectal cancer patient (same patient as for SW480).
All cell lines were transduced for TdTomato (ﬂuorescence)
and luciferase (bioluminescence) expressions and kindly pro-
vided by Vectalys® company. These cells are indicated as “cell
line name- T-Luc” in the study. Cell lines were maintained at
37C and 5% CO2 in Dulbecco’s Modiﬁed Eagle Medium
(Gibco, Life Technologies) supplemented with 10% heat-
inactivated fetal calf serum (Gibco, Life Technologies), 2 mM
glutamine (Gibco, Life Technologies).
Human colon resection samples were obtained from patients
suffering from colorectal cancer and treated at the Toulouse
University Hospital. Patients gave informed consent, and tissues
samples were included in the registered COLIC collection (DC-
2015-2443). Tissues used in our study were harvested in
healthy normal zones, at least 10 cm away from the tumor.
Mice
SCID Beige were purchased from Charles River Laboratoire
(France CRLF) and maintained in Toulouse-Purpan animal facil-
ities. Female mice at 7 weeks of age were used. For the guidelines
on animal welfare, we followed the European directive 2010/63/
EU. For administrations, including routes and volumes, we fol-
lowed the good practice guide published in 2001. The ethics
committee has approved our protocol (2015-U1043-CD-20).
In vitro imaging of cell lines
Cell lines were plated at 1x105 cells per well in black 96-well
plate overnight. Luciferase substrate, D-luciferin, was added at
0.3 mg/well in phosphate saline buffer (PBS), 5 min before imag-
ing with a highly sensitive cooled charge-coupled device camera
(IVIS Spectrum Lumina II; Perkin Elmer). Wells were then
rinsed with PBS and ﬂuorescent acquisition was performed for
Tomato ﬂuorescence emission (excitation: 535 nm, emission:
580 nm) with the IVIS camera (Supporting Information Fig. 1).
Quantity of bioluminescent or ﬂuorescent photons emitted by
cells was measured in well-surrounding region of interest (ROI)
in plates, using Living Image® 4.4 software (Perkin Elmer). Bio-
luminescence was quantiﬁed in photons (ph)/sec(s)/cm2/stera-
dian (sr) and ﬂuorescence was quantiﬁed in [ph/cm2/s/sr]/
[υW/cm2] using the Living Images version 4.5.5. (Perkin Elmer).
Transplantation and growth of human tumors in mice
Orthotopic colon tumors were established by injecting 1 × 106
colon carcinoma cells subsereously in the caecum (IC) in 20 μL
of PBS as previously described15. Progression of luciferase-
expressing tumors was monitored using bioluminescent imaging
performed with IVIS camera (IVIS Spectrum Lumina II; Perkin
Elmer) and intraperitoneal (IP) injection of 100 μL D-luciferin
(OZ Biosciences) in 30 mg/mL of PBS.15 Mice were sacriﬁced
as overt signs of pain and stress. Primary caecum tumors, livers
and lungs were then harvested and placed in 6-well plates.
Organs were imaged for their Tomato ﬂuorescence emission
with IVIS camera. Quantity of bioluminescent or ﬂuorescent
photons emitted by tumors was measured in total mice region of
interest (ROI) for mice analysis and in well-surrounding ROI for
plates organs analysis, using Living Image® 4.4 software (Perkin
Elmer). Bioluminescence was quantiﬁed using the Living Images
version 4.5.5. (Perkin Elmer) in photons (ph)/sec(s)/cm2/sr and
ﬂuorescence was quantiﬁed in [ph/cm2/s/sr]/[υW/cm2].
Polymerase chain reaction (PCR) and capillary
electrophoresis
For in vitro cell lines analysis, the four different cell lines were
harvested from tissue culture, rinsed in PBS and lysed. For
in vivo tumors analysis, primary-caecum tumors, livers and lungs
were excised from mice at various time points, snap-froze,
crushed and lysed. RNA was extracted from all tissues using the
NucleoSpin® RNA/Protein kit (Macherey-Nagel) following the
manufacturer instruction. RNA (3 μg) was reverse transcribed
using Maxima First Strand cDNA synthesis kit for RT-PCR
(ThermoFisher Scientiﬁc). The resulting cDNA was used for
ampliﬁcation. PCR were performed using Fast cycling PCR kit
(Qiagen) in a reaction volume 20 μL using 3 μL of cDNA (1/5
dilution), 10 μL of 2X PCR Buffer and 0.5 μM of primers spe-
ciﬁc for FAK mRNA alternatively spliced variants. The following
primers were used: FAK0/ FAK7 human (h) primers (forward
3 (F3): 50-TCTCTGTGTCAGAAACAGATGATT30-5-Carboxy-
ﬂuorescine (FAM)-coupled reverse 2 (R2): 50CTGACGCATT
GTTAAGGCTTC3 0), FAK28/ FAK7,28 hprimers (F4: 50CTCCTT
CTACGGAAACAGATGATT30- FAM-R2), FAK6/ FAK6,7 hpri-
mers (F5: 50TCTCTGTGTCAGATGAAATTAGTGG30-FAM-
R2) and FAK6,28/ FAK6,7,28 hprimers (F6: 50CTCCTTCTAC
GGATGAAATTAGTG30-FAM-R2). Fast cycling PCR ampliﬁca-
tion consists in initial denaturation step (95C for 5 s) followed
by 35 cycles of ampliﬁcation (96C 5 s, 58C 5 s and 68C 9 s)
and a ﬁnal extension of 1 min at 72C.
PCR products were analyzed in a genetic analyzer ABI
3130xl (Applied Biosystems, Saint Aubin, France). Brieﬂy, 1 μL
of PCR product (pure, 1/10 or 1/20 dilutions) was mixed with
8.7 μL of Hi-Di formamide (Applied Biosystems) and 0.3 μL of
GS-500-ROX (DNA Size Marker with fragments ranging from
35 to 500 bp used to size PCR products, ThermoFisher Scien-
tiﬁc). Analysis were performed with Peak Scanner 2® software.
FAK mRNA variants were independently detected as single peak
at the corresponding product size (see Supporting Information
496 FAK alternative splice mRNA variants expression pattern in colorectal cancer
Int. J. Cancer: 145, 494–502 (2019) © 2019 The Authors. International Journal of Cancer published by John Wiley & Sons Ltd on behalf of UICC
M
ol
ec
ul
ar
C
an
ce
r
B
io
lo
gy
Fig. 2 as an example): for F3-FAMR2: FAK0 = 178 bp and
FAK7 = 199 bp, F4-FAMR2: FAK28 = 178 bp and FAK7,28 =
199 bp, F5-FAMR2: FAK6 = 196 bp and FAK6,7 = 217 bp,
F6-FAMR2: FAK6,28 = 196 bp and FAK 6,7,28 = 217 bp.
Quantitative real-time PCR
Quantitative (q)RT-PCR was performed on the capillary
electrophoresis-detected FAK mRNA variants using LightCycler
480 SYBR Green I Master (Roche, Boulogne-Billancourt, France).
Brieﬂy, per sample 45 ng of cDNA was mixed with 5 μL of Syber
Green Mix and 0.5 μM of the following primers: hF3-R2 (for
FAK0), hF4-R2 (50ATTTCTCTCTCACGCTGTCC30) (for
FAK28), hF5-R2 (for FAK6) and forward hHPRT primer (CC
TGGCGTCGTGATTAGTGA) and reverse hHPRT primer
(CGAGCAAGACGTTCAGTCCT) (for housekeeping gene).
hHPRT has been validated as speciﬁc forHomo sapiens that does
not cross-react withMus musculus (data not shown). qPCR reac-
tion was performed for 45 cycles in a LightCycler 480 (Roche)
and analyzed using LightCycler 480 SW1.5.1 software.
Statistical analysis
Results are expressed as the mean  S.E.M. The difference in
tumor growth and qPCR were analyzed by one-way or two-
way ANOVA. When two columns of data have been com-
pared, the Student t test has been used. A p value <0.05 was
considered signiﬁcant.
Results
CRC tumor development after SW480, SW620, HT29 and
HCT116 cell lines orthotopic implantation in SCID
beige mice
The four CRC human cell lines (SW480, SW620, HT29 and
HCT116) are known for their differential growth and invasive
capacities following intracaecal (IC) xenografting in immuno-
deﬁcient nude mice.16,17 However, the immunodeﬁcient mouse
models previously used displayed a limited metastatic potential
of the tumor cells due to the presence of natural killer
(NK) cells. In order to favor the metastatic process by eliminat-
ing NK antitumor functions, we used here SCID beige mice.
The four cell lines, emitting similar levels of either luminescent
or ﬂuorescent signals in vitro (Supporting Information Fig. 1),
were injected IC and tumor development was monitored over
time using an in vivo imaging system allowing noninvasive
monitoring of the disease progression in living animals.
All the four implanted CRC cell lines produced solid growing
tumors, as detected by the measure of the luminescence emis-
sions at the indicated days post cells engraftment (Fig. 2a), but
with different growth rates while the same number of cells was
originally engrafted in the caecum (Fig. 2b). Both SW480- and
SW620-induced tumors grew at slow rate during the full 35 days
of follow-up. HT29-induced tumors grew at a similar slow rate
until approximatively days 25–28 but then displayed a rapid
growth until the end-point of the experiment. HCT116-induced
tumor grew faster than the ones generated by the other cell lines
but the growth rate remained stable passed day 20/25. The
decrease in the luminescence signal in HCT116 tumors might
be due to the development of hypoxic area in tumors associated
with their rapid growth. Indeed, the Fireﬂy luciferase activity is
highly oxygen-dependent since it uses both oxygen and adeno-
sine triphosphate to catalyze the emission of light from luciferin.
Since solid tumors are known to develop hypoxic area while
growing, the availability of the oxygen for the luciferase is lim-
ited, reducing the bioluminescence emission and leading to an
underestimation of the number of alive luciferase-expressing
tumor cells in vivo (Fig. 2b).
In order to discriminate between the primary tumor and the
metastasis capacities of the different cell lines, we performed an
ex vivo analysis of the TdTomato ﬂuorescence of the different
organs. In the caecum, this analysis conﬁrmed the previous obser-
vations of tumor progression obtained by bioluminescence emis-
sion analyses (Fig. 3). Concerning liver and lung metastases
development, the four CRC cell lines behaved differently. No
TdTomato ﬂuorescence was detected in the liver and lungs of the
SW480-IC-injected mice. In the SW620-IC-engrafted mice, liver
metastases were detected from day 80. InHT29-IC-engraftedmice,
TdTomato ﬂuorescence was detected from day 35 in the liver but
only traces of metastases could be detected in the lungs from day
45. Finally, regarding HCT116 cells, liver and lungmetastases were
clearly detected as early as day 35 highlighting the high aggressive-
ness capacities of this CRC cell line. By comparison with HCT116,
only a small amount of liver metastases was detected at days
45 and 80 for HT29 and SW620, respectively (Fig. 3).
Thus, our data obtained from the orthotopic CRC model
in SCID beige mice demonstrate that HCT116 and HT29 cells
are more aggressive, with higher proliferative and invasive
properties, compared to SW620 and SW480 cells.
Expression of FAK alternative splice variants mRNA in
SW480, SW620, HT29 and HCT116 CRC cell lines
Folllowing the characterization of the metastatic potential of the
four human CRC cell lines in our model, we ﬁrst investigated the
expression of FAK splice variants in those cells in vitro, before
their engraftment in mice. Our aim was to characterize the
in vitro basal intrinsic regulation of the FAK mRNA splice vari-
ants expression independently from an expression regulation
potentially controlled by the microenvironment in vivo.
The RT-PCR products for the following human FAK
mRNA splice variants: FAK0, FAK6, FAK7, FAK28, FAK6,7,
FAK6,28, FAK7,28, FAK6,7,28 were analyzed for the four CRC
cell lines using capillary electrophoresis, since this technique
is highly sensitive and allows the speciﬁc discrimination of the
RT-PCR products based on the base pair sizes. As shown in
Table 1, FAK0, FAK6 and FAK28 were the only three mRNA
variants detected in the four tested CRC cell lines.
The quantiﬁcation of FAK0, FAK6 and FAK28 mRNA was
then performed by qRT-PCR. Considering that the SW480
cell line presents the lowest aggressiveness capacity, it was
chosen as reference of the basal level of FAK splice variant
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expression for the comparison with the three other cell lines
(Figs. 4 and 5).
The mRNA of FAK0, the common form of FAK, was highly
expressed in the aggressive cell lines HT29 and HCT116 com-
pared to the less invasive cell lines SW620 and SW480, and to
primary non tumoral colon cells isolated from normal tissue
distant from the primary tumor site in CRC patients colon
resections (Fig. 4). FAK6 and FAK28 mRNA expressions did
not signiﬁcantly differ between the four cell lines but were
highly expressed in the four CRC cell lines compared to non
tumoral cells which expressed low level of FAK28 and only
traces of FAK6 (Fig. 4).
Altogether, these data show that CRC cell lines are charac-
terized by a high level of FAK6 and FAK28 transcripts com-
pared to normal (non tumoral) colon cells. Moreover, the CRC
cell lines with the highest invasive potential display high levels
of FAK0 associated with FAK6 and FAK28 transcripts.
Expression of FAK0, FAK6 and FAK28 mRNA splice variants in
CRC primary tumors and in distant metastases after
orthotopic implantation of CRC cell lines
After the intracaecal orthotopic implantation of SW480, SW620,
HT29 and HCT116 CRC cell lines, human FAK mRNA spliced
variants FAK0, FAK6 and FAK28 were quantiﬁed by qRT-PCR
Figure 2. Comparative tumor growth of four human colon carcinoma cell lines after orthotopic implantation in SCID beige mice. SCID Beige mice
were implanted intracaecally (IC) with 1 × 106 SW480 T-Luc, SW620 T-Luc, HT29 T-Luc or HCT116 T-Luc cells. Bioluminescent emission imaging
allowed the monitoring of tumor development along the time. (a) General mice status: Representative bioluminescent imaging of one mouse per
group from day 10 after implantation. Imaging was followed up until day 80 for SW480 T-Luc and SW620 T-Luc cell lines. Setting is applied in
counts. (b) Comparative time-course of tumor growth: Bioluminescence emitted by tumors was quantiﬁed in total body regions of interest (ROI)
and caecum ROI and then normalized as fold increase of emission at day 7 after implantation. n = 5–7mice per group, average  S.E.M.
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within caecum, liver and lung samples. Importantly, as observed
for the in vitro cell lines, only FAK0, FAK6 and FAK28 were
expressed in vivo as assessed using PCR followed by capillary
electrophoresis performed on caecum, liver and lungs extracted
at various time-points after HT29 and HCT116 engraftment
(Supporting Information Table I). Here we decided to perform
Figure 3. Differentmetastatic potential of the four human colon carcinoma cell lines implanted in SCID beigemice. Primary tumors (caecum) and organs
withmetastases (liver, lungs) were harvested fromSW480 T-Luc (a), SW620 T-Luc (b), HT29 T-Luc (c) and HCT116 T-Luc (d) tumor-bearingmice at various
cancer development time-points. Counts of TdTomato ﬂuorescencewere normalized on in vitro quantiﬁcation for each cell line (n = 3–4mice,
average  S.E.M.). Representative ﬂuorescence imaging of onemouse per group is shown. ****p < 0.0001, ***p < 0.0005, **p < 0.005, *p < 0.05.
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the analysis only on the most aggressive cell lines, which dis-
played the highest levels of expression for these splice variants.
In line with our results on the expression measured in the
cell lines in vitro, FAK0 expression level in primary tumors
(caecum) was higher in HT29 and HCT116 cells compared to
SW480 and SW620 cells at day 7 post-engraftment (Fig. 5a).
At day 45, the FAK0 transcript expression level in caecum-
tumors was only signiﬁcantly higher in HT29 compared to
the other cell lines (Fig. 5b). Regarding FAK6 transcript in the
primary tumors, at day 7 after engraftment, the expression
was increased in HT29 cells compared to other cell lines
(Fig. 5a). At day 45, a stage where liver metastases from the
HCT116 and HT29 cell lines were well established (Fig. 3),
FAK6 expression level was signiﬁcantly increased in tumor
samples obtained from HT29 cells, and tends to be upregu-
lated in HCT116 cells compared to non-invasive SW480 and
less-invasive SW620 cells (Fig. 5b). FAK28 mRNA from cae-
cum samples was only measurable at day 45 using qRT-PCR
(despite earlier traces detected by capillary electrophoresis,
Supporting Information Table I) with no signiﬁcant differ-
ences between the tumor samples obtained from the different
CRC cell lines (Fig. 5b).
At day 45, metastases were only detected in mice grafted
with HT29 or HCT116 cells (Fig. 3), and FAK0 and FAK6
transcripts are measured in both liver and lungs metastases
while the expression of FAK28 was only found in liver metas-
tases (Figs. 5c and 5d).
Altogether, these results conﬁrmed an association between
FAK0 and FAK6 expressions and the aggressiveness of HT29
and HCT116 cells.
Discussion
The non receptor tyrosine kinase FAK is now well described
to play a crucial role in several steps of cancer processes, driv-
ing either tumor growth or metastasis.18 FAK involvement in
metastasis process implies the regulation of tumor cell motility
and invasion via the control of focal adhesion, cytoskeletal
dynamics or the modulation of matrix metalloproteinase
expression and thus, the interaction of the tumor cells with
their microenvironment.18 Moreover, FAK also regulates cell
survival as well as cancer-stem cell renewal, two crucial events
for the development of secondary tumors.18
During the 1990s, a new level of FAK regulation has been
found with the identiﬁcation of several FAK splice variants gen-
erated after alternative splicing, as described above.7,19 In our
study, the expression of FAK mRNA splice variants comprising
exons 13 (FAK28), 14 (FAK6) or none (FAK0) was investigated
in four human colorectal cancer cell lines with different inva-
sive properties, in vitro and in vivo after orthotopic xeno-
engraftment of these cells in the caecum of SCID beige mice.
Table 1. Analysis by capillary electrophoresis of the pattern of FAK alternative splice variant mRNAs expression in the four human CRC cell lines
(+: Variant detected, −: Variant not detected)
FAK variants CRC cell lines 0 7 28 7,28 6 6,7 6,28 6,7,28
SW480 T-Luc + − + − + − − −
SW620 T-Luc + − + − + − − −
HT29 T-Luc + − + − + − − −
HCT116 T-Luc + − + − + − − −
Figure 4. Quantitative analyses for FAK0, FAK6 and FAK28 mRNA variants expression in vitro in normal epithelial cells and the four-tumor colon
cell lines used in our study. qRT-PCR was performed to quantify the expression of (a) FAK0 (b) FAK6 and (c) FAK28 mRNA in non tumoral colon
epithelial cells isolated from tumor-bearing patients (n = 5, average  S.E.M.) and in SW480 T-Luc, SW620 T-Luc, HT29 T-Luc and HCT116 T-
Luc tumor cell lines from in vitro tissue culture (n = 6, average  S.E.M.). Relative Expression of all mRNA has been normalized on the
relative expression of SW480: ***p < 0.001, **p < 0.01.
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The combination of qRT-PCR and capillary electrophoresis
approaches allowed us to obtain data with high sensitivity and
speciﬁcity, and to exclude other FAK mRNA splice variants
(FAK7, FAK6,7, FAK6,28, FAK7,28, FAK6,7,28) from our analyses.
FAK0, coding for the common FAK isoform, was initially
known to be the most abundant form of the kinase in tissues,
including the colon. In the present study, before (in vitro) and
after (in vivo) the cells engraftment, FAK0 mRNA was highly
expressed in CRC tumor cells and was speciﬁcally increased
in the two more aggressive cell lines, namely HT29 and
HCT116. The elevated growth and invasion capacities of these
two cell lines have been demonstrated by others16,17 and were
conﬁrmed in our study.
Regarding FAK6 and FAK28, both isoforms were found
overexpressed in the SW480, SW620, HT29 and HCT116 cell
lines compared to human normal epithelial cells, indepen-
dently of their histological grade and genetic mutations. The
leading cause of death among CRC patients is distant metasta-
ses whose formation can be promoted by FAK and its signal-
ing partner p60-Src kinase through an epithelial–mesenchymal
transition.20 FAK6 splice variant differs from FAK0 by the
alternative addition of spliced exons near the exon 15 coding
for the autophosphorylation site Tyrosine 397. Interestingly,
FAK6 has been described with increased phosphorylation of
this tyrosine that represents a binding site for Src kinases.7
One month after their orthotopic engraftment in mice caecum,
HCT116 and HT29 cells generated metastases in liver and
lungs, in line with the pathophysiological spreading of CRC in
human. At day 45, both FAK0 and FAK6 mRNA were found
overexpressed in HCT116 and HT29 primary tumors com-
pared to nonaggressive cell lines, and were also detected in
their liver and lung metastases. These data suggest a putative
implication of FAK0 and FAK6 in the CRC metastatic process
and corroborate the association between those isoforms and
the tumor aggressiveness demonstrated in other tumor models
such as acute myeloid leukemia or nonsmall cell lung cancer.4,5
As demonstrated for these two cancers, we could hypothesize
that FAK0 and FAK6 may represent potential aggressiveness
markers also in CRC.
Regarding FAK28, while its expression was detected
in vitro, once in vivo, this splice variant is not found anymore
in the cells forming the primary tumor at early stage (day 7).
However, its expression is again detected in late primary
tumors (Day 45) and subsequent liver metastasis only origi-
nating from the most aggressive cell lines. The fact that FAK28
is no more detected at the very early stage of the tumor pro-
cess suggests that this isoform is not crucial for the initial
tumor mass development. However, its detection in in vitro
Figure 5. Quantitative analyses for FAK0, FAK6 and FAK28 mRNA variants expression at early and late steps of human colon tumors
development in an in vivo mouse model. qRT-PCR was performed to quantify the expression of FAK0, FAK6 and FAK28 mRNA variants from
caecum primary tumors, livers and lungs metastases samples harvested early at day 7 (caecum-a) or late at days 45 (caecum-b; liver-c and
lungs-d) after the orthotopic implantation of tumor cell lines as described in Material and Methods. Relative Expression of all mRNA has been
normalized and statistics have been calculated in comparison to the relative expression of mRNAs in SW480 (a and b) or mRNAs in HT29
(c and d): ***p < 0.0005, **p < 0.01, *p < 0.05.
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cell tissue-culture on plastic plates, where cells display strong
physical interactions with their support, as well as in advanced
primary tumors and their associated metastasis, when cells
must develop new interaction capacities with their environ-
ment in order to migrate and invade the tissues. This suggests
a putative more speciﬁc role of this FAK isoform in the inter-
action of the cell with its support. Interestingly, the box
28 coded by exon 13, maintained in the FAK28 mRNA vari-
ant, exhibits an inversed consensus sequence for calmodulin,
which could favor the binding of FAK to cell adhesion mole-
cules.21 These data suggest an eventual role of this splice vari-
ant in the regulation of cells with their direct environment by
the modulation of the functions of cell adhesion molecules.
Compared to other cell lines, in HT29 cells, FAK6 mRNA is
increased shortly after engraftment in the caecum. On the
other hand, FAK28 mRNA is measured in liver metastases and
not detected in lung metastases. Further studies would be
needed to elucidate putative differential role of the FAK
mRNA splice variants depending on microenvironmental
niche of tumor cells. Furthermore, beside its potential role in
the migration of tumor cells to the liver, a possible association
of FAK28 with cell adhesion molecules might be involved in
the immune evasion. Indeed, it has been demonstrated that in
response to stimulation of the adhesion molecule NCAM, a
FAK N-terminal fragment together with a C-terminal fragment
of the adhesion molecule cotranslocate into the nucleus.22 More-
over a nuclear FAK activity has been described to regulate che-
mokine and cytokine expressions in tumor cells leading to a
control of tumor Treg levels as well as antitumor immune eva-
sion.23 So far, the regulation processes and functional roles of the
FAK28 variant are unknown and our work highlights for the ﬁrst
time the potential signiﬁcance of FAK28 in cancer.
In conclusion, although targeting the common form of FAK,
aka FAK0, might not be a good strategy based on the numerous
role of this kinase in physiological processes, FAK6 or FAK28
could represent interesting therapeutic targets in CRC and justify
to be further investigated in vitro and in vivo, possibly with new
tools that would speciﬁcally block each isoforms.
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